Evidence map›Paper›PMID 29145483›Full record

Trial reportPLoS pathogens2017

Sequential inflammatory processes define human progression from M. tuberculosis infection to tuberculosis disease.

Thomas J Scriba, Adam Penn-Nicholson, Smitha Shankar, Tom Hraha, Ethan G Thompson, David Sterling, Elisa Nemes, Fatoumatta Darboe, Sara Suliman, Lynn M Amon and 13 more

Registry-linked trialOpen access · goldAbstract readClinical Trial
In one paragraph

Trial report in PLoS pathogens, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01119521 (Phase I Study of Whether Preclearance of Latent M. Tuberculosis), which is not on this map. Cited by 162 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
162citing papers in PubMed, 2 pooled it
14.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01119521 phase1completednot on this map

Phase I Study of Whether Preclearance of Latent M. Tuberculosis (MTB) Infection With Isoniazid (INH) Enhances Specific Immune Responses to MTB Following Subsequent BCG Revaccination in Healthy, HIV-Uninfected, Tuberculin Skin Test Positive Adults

TypeinterventionalSponsorNational Institute of Allergy and Infectious Diseases (NIAID)Ran2010 to 2013Enrolled82ConditionsTuberculosisArmsBCG strain Danish, Isoniazid
3 · Its place in the literature

Who cites it

162 citing papers in PubMed, 2 syntheses or guidelines pooled it, 245 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Doxycycline host-directed therapy in human pulmonary tuberculosis.The Journal of clinical investigation · 2021
    Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Restricted MHC-II trafficking inbioRxiv : the preprint server for biology · 2026
    Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Observational

102 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 5 institutions in 2 countries.

Thomas J ScribaSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine & Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.ORCID 0000-0002-0641-1359
Adam Penn-NicholsonSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine & Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.ORCID 0000-0002-1883-0059
Smitha ShankarThe Center for Infectious Disease Research, Seattle, WA, United States of America.
Tom HrahaSomalogic Inc, Boulder, CO, United States of America.ORCID 0000-0001-8027-2177
Ethan G ThompsonThe Center for Infectious Disease Research, Seattle, WA, United States of America.
David SterlingSomalogic Inc, Boulder, CO, United States of America.
Elisa NemesSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine & Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
Fatoumatta DarboeSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine & Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.ORCID 0000-0001-5945-3715
Sara SulimanSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine & Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.ORCID 0000-0002-5154-576X
Lynn M AmonThe Center for Infectious Disease Research, Seattle, WA, United States of America.ORCID 0000-0002-6420-7698
Hassan MahomedSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine & Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.ORCID 0000-0001-6775-9482
Mzwandile ErasmusSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine & Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
Wendy WhatneySouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine & Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
John L JohnsonTuberculosis Research Unit, Department of Medicine, Case Western Reserve University and University Hospitals Case Cleveland Medical Center, Cleveland, OH, United States of America.
W Henry BoomTuberculosis Research Unit, Department of Medicine, Case Western Reserve University and University Hospitals Case Cleveland Medical Center, Cleveland, OH, United States of America.ORCID 0000-0001-5760-9595
Mark HatherillSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine & Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
Joe ValvoThe Center for Infectious Disease Research, Seattle, WA, United States of America.
Mary Ann De GrooteSomalogic Inc, Boulder, CO, United States of America.
Urs A OchsnerSomalogic Inc, Boulder, CO, United States of America.ORCID 0000-0003-0959-0265
Alan AderemThe Center for Infectious Disease Research, Seattle, WA, United States of America.
Willem A HanekomSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine & Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
Daniel E ZakThe Center for Infectious Disease Research, Seattle, WA, United States of America.
other members of the ACS cohort study team
University of Cape Town · ZACenter for Infectious Disease Research · USSomaLogic (United States) · USUniversity Hospitals of Cleveland · USWestern Cape Department of Health · ZA

Funding

Technology CoreU19AI106761 · NIAID · SEATTLE BIOMEDICAL RESEARCH INSTITUTE · PI SHERMAN, DAVID R, ZAK, DANIEL E · 2013 to 2017
$18.9M
TUBERCULOSIS SUPPLEMENTD43TW000231 · FIC · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI ABDOOL KARIM, QUARRAISHA · 1993 to 2014
$13.1M
Tuberculosis Prevention Research Unit /TBRU/-266095383N01AI095383 · NIAID · CASE WESTERN RESERVE UNIVERSITY · 2000 to 2005
$5.6M
Host determinants of protection against tuberculosis in adolescentsR01AI087915 · NIAID · UNIVERSITY OF CAPE TOWN · PI SCRIBA, THOMAS JENS · 2011 to 2015
$3.3M
FIC NIH HHS D43 TW000231NIAID NIH HHS N01 AI070022NIAID NIH HHS N01 AI095383NIAID NIH HHS R01 AI087915NIAID NIH HHS U19 AI106761
6 · The paper itself

Abstract

Our understanding of mechanisms underlying progression from Mycobacterium tuberculosis infection to pulmonary tuberculosis disease in humans remains limited. To define such mechanisms, we followed M. tuberculosis-infected adolescents longitudinally. Blood samples from forty-four adolescents who ultimately developed tuberculosis disease (“progressors”) were compared with those from 106 matched controls, who remained healthy during two years of follow up. We performed longitudinal whole blood transcriptomic analyses by RNA sequencing and plasma proteome analyses using multiplexed slow off-rate modified DNA aptamers. Tuberculosis progression was associated with sequential modulation of immunological processes. Type I/II interferon signalling and complement cascade were elevated 18 months before tuberculosis disease diagnosis, while changes in myeloid inflammation, lymphoid, monocyte and neutrophil gene modules occurred more proximally to tuberculosis disease. Analysis of gene expression in purified T cells also revealed early suppression of Th17 responses in progressors, relative to M. tuberculosis-infected controls. This was confirmed in an independent adult cohort who received BCG re-vaccination; transcript expression of interferon response genes in blood prior to BCG administration was associated with suppression of IL-17 expression by BCG-specific CD4 T cells 3 weeks post-vaccination. Our findings provide a timeline to the different immunological stages of disease progression which comprise sequential inflammatory dynamics and immune alterations that precede disease manifestations and diagnosis of tuberculosis disease. These findings have important implications for developing diagnostics, vaccination and host-directed therapies for tuberculosis.

trial registrationClincialtrials.gov, NCT01119521.

Indexed as

Mycobacterium tuberculosisAdolescentChildDisease ProgressionHumansInflammationT-LymphocytesTuberculosisVaccinesVaccines

Identifiers

PMID29145483
PMCPMC5689825
OpenAlexW2769926657

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.